← back to search

Mark Frasier

Michael J. Fox Foundation ·
Area of research
Neurology · Cellular and Molecular Neuroscience
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Nuclear Receptors and Signaling, and Neuroinflammation and Neurodegeneration Mechanisms.
h-index
33
citations
8,050
works
108
NIH funding
primary concept
email

Recent publications

The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
Nature Medicine 2025cited by 71position: middledoi
<i>LRRK2</i> -associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization
Brain Communications 2025cited by 15position: middledoi
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
The Lancet Neurology 2024cited by 540position: middledoi
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts
npj Parkinson s Disease 2024cited by 34position: middledoi
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
The Lancet Neurology 2023cited by 671position: middledoi
A proteogenomic view of Parkinson’s disease causality and heterogeneity
npj Parkinson s Disease 2023cited by 53position: middledoi
Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors
Sensors 2022cited by 26position: middledoi
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
npj Parkinson s Disease 2022cited by 18position: middledoi
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
Movement Disorders 2020cited by 196position: middledoi
Differences in the Presentation and Progression of Parkinson's Disease by Sex
Movement Disorders 2020cited by 100position: middledoi
Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease
Movement Disorders 2019cited by 139position: middledoi
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)
Parkinsonism & Related Disorders 2019cited by 22position: middledoi
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Annals of Clinical and Translational Neurology 2018cited by 678position: middledoi
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
Movement Disorders 2018cited by 203position: middledoi
Finding useful biomarkers for Parkinson’s disease
Science Translational Medicine 2018cited by 150position: middledoi
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
Neurology 2017cited by 151position: middledoi
Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features
Movement Disorders 2017cited by 147position: middledoi
Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
Journal of Neuroinflammation 2017cited by 104position: middledoi
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study
Acta Neuropathologica 2016cited by 219position: middledoi
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort
Movement Disorders 2016cited by 64position: lastdoi
Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease
Neurobiology of Disease 2014cited by 227position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Kenneth Marek · Montreal Neurological Institute and Hospital3 papers (2017–2020)Peggy Taylor · BioLegend (United States)3 papers (2017–2019)Tanya Simuni · Northwestern University3 papers (2019–2022)Andrew Siderowf · University of Pennsylvania3 papers (2019–2022)Brit Mollenhauer · Short and Associates (United States)3 papers (2017–2020)Leslie M. Shaw · Siemens (United States)2 papers (2017–2019)Christopher S. Coffey · University of Iowa2 papers (2019–2020)Howard Andrews · New York University2 papers (2016–2017)Arthur W. Toga · UtopiaCompression (United States)2 papers (2019–2020)Samuel Frank · Beth Israel Deaconess Medical Center2 papers (2016–2017)Catherine Kopil · University of Alabama at Birmingham2 papers (2016–2017)Lana M. Chahine · University of Pittsburgh2 papers (2019–2020)Roy N. Alcalay · University of Alabama at Birmingham2 papers (2016–2017)John Seibyl · University of Arizona2 papers (2019–2020)Daniel Weintraub · California University of Pennsylvania2 papers (2019–2020)Penelope Hogarth · Oregon Health & Science University2 papers (2016–2017)Jennifer G. Goldman · Northwestern University2 papers (2016–2017)Paul Tuite · University of Minnesota2 papers (2016–2017)Margaret Sutherland · University of Saskatchewan2 papers (2016–2017)Amy W. Amara · University of Alabama at Birmingham2 papers (2016–2017)